Neuphoria TherapeuticsNEUP
13F holders, Q1 2025 (March 31)7holders −1
3new positions
4sold out
$5.73avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Neuphoria Therapeutics Inc. (NEUP) in their 13F filings, down 1 from Q4 2024. 3 opened new positions and 4 sold out. The largest holders were AdvisorShares Investments LLC ($397K), Lynx1 Capital Management LP ($264K) and Prosperity Wealth Management, Inc. ($157K).
- Company
- Neuphoria Therapeutics Inc.
- CUSIP
- 64136E102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $611K |
| Exits | 4 | $78K |
All 13F filers, Q4 2024 → Q1 2025: 106,859 shares bought and 23,465 shares sold, net +83,394 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| AdvisorShares Investments LLC | 0.08% | New | 69,659 | $397K |
| Lynx1 Capital Management LP | 0.09% | No change | 45,806 | $264K |
| Prosperity Wealth Management, Inc. | 0.07% | New | 27,200 | $157K |
| Merck & Co., Inc. | 0.04% | No change | 10,027 | $58K |
| Cyndeo Wealth Partners, LLC | 0.00% | New | 10,000 | $58K |
| Rhumbline Advisers | 0.00% | Reduce -62.5% | 415 | $2K |
| Morgan Stanley | 0.00% | No change | 7 | $40 |
"% of holder's portfolio" is NEUP's weight in each manager's 13F, not the share of Neuphoria Therapeutics Inc. the manager owns.